Comparison of Nimesulide vs Diclofenac sodium in patients with gout

Compared to Diclofenac (75 mg twice daily), Nimesulide (100 mg twice daily) shows a better analgesic effect in gout-affected people.

This study aimed to investigate the efficacy of Nimesulide and Diclofenac sodium for gout management.

The study consisted of 40 volunteers diagnosed with gout, comprising 33 males and 7 females. Participants were segregated into two groups. The first group, referred to as the "main group," comprised 20 gout subjects who were administered Nimesulide tablets at a dosage of 100 mg twice daily.

In order to assess the efficacy of Nimesulide, the second group (referred to as the "control group") received Diclofenac sodium at a dosage of 75 mg twice daily. Both groups followed the therapeutic regimen for a duration of 7 days.

Nimesulide tablets demonstrated the highest efficacy in terms of both the speed and intensity of the analgesic effect. Within 20 minutes, 7 subjects in the first group reported a decrease in joint pain, which increased to 13 subjects post 40 minutes. After one hour, 16 people in the first group rated the effect as good, with a significant reduction in pain observed in 6 of them.

Conversely, in the second group, only 3 subjects experienced a decline in pain, and that too after 1-1.5 hours. All volunteers in the first group acknowledged the anti-inflammatory and analgesic effect of Nimesulide tablets, while only 2 subjects in the second group experienced the effect of Diclofenac. Nimesulide successfully halted arthritis attack in 45% of people (n = 9) in the first group, compared to only 10% of people (n = 2) in the second group.

For gout management, Nimesulide has better effectiveness when compared to Diclofenac.